EP 3066089 B1 20191106 - SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
Title (en)
SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
Title (de)
SUBSTITUIERTE N-ACETYL-L-CYSTEIN-DERIVATE UND VERWANDTE VERBINDUNGEN
Title (fr)
DÉRIVÉS DE N-ACÉTYL-L-CYSTÉINE SUBSTITUÉE ET COMPOSÉS ASSOCIÉS
Publication
Application
Priority
- US 201361902052 P 20131108
- US 201361902669 P 20131111
- US 2014064581 W 20141107
Abstract (en)
[origin: US9012674B1] A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
IPC 8 full level
C07D 327/04 (2006.01); A61K 31/185 (2006.01); A61P 25/00 (2006.01); C07C 323/57 (2006.01); C07C 327/34 (2006.01); C07D 241/08 (2006.01)
CPC (source: EP US)
A61P 9/10 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/14 (2018.01 - EP); A61P 25/18 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 25/30 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07C 323/57 (2013.01 - EP US); C07C 323/58 (2013.01 - EP US); C07C 323/59 (2013.01 - EP US); C07C 323/60 (2013.01 - EP US); C07C 327/26 (2013.01 - US); C07C 327/32 (2013.01 - US); C07C 327/34 (2013.01 - EP US); C07C 329/06 (2013.01 - EP US); C07D 241/08 (2013.01 - EP US); C07D 277/08 (2013.01 - EP US); C07D 277/14 (2013.01 - EP US); C07D 327/04 (2013.01 - EP US); A61K 31/165 (2013.01 - EP US); A61K 31/265 (2013.01 - EP US); A61K 31/426 (2013.01 - EP US); A61K 31/513 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
US 2015133544 A1 20150514; US 9012674 B1 20150421; AU 2014346591 A1 20160526; AU 2014346591 B2 20180927; AU 2018282446 A1 20190117; AU 2018282446 B2 20200723; AU 2020257084 A1 20201119; CA 2929655 A1 20150514; CA 2929655 C 20230613; DK 3066089 T3 20200127; EP 3066089 A1 20160914; EP 3066089 B1 20191106; EP 3674297 A1 20200701; ES 2765236 T3 20200608; HU E048345 T2 20200728; JP 2016537338 A 20161201; JP 2018080164 A 20180524; JP 2020121993 A 20200813; JP 2022003063 A 20220111; JP 6559756 B2 20190814; JP 6691044 B2 20200428; JP 6952825 B2 20211027; JP 7170811 B2 20221114; LT 3066089 T 20200225; PL 3066089 T3 20200430; PT 3066089 T 20200129; SI 3066089 T1 20200331; US 10112897 B2 20181030; US 10358414 B2 20190723; US 10961187 B2 20210330; US 2015133470 A1 20150514; US 2017183303 A1 20170629; US 2017210716 A1 20170727; US 2019315683 A1 20191017; US 2021395194 A1 20211223; US 2024059649 A1 20240222; US 9630937 B2 20170425; WO 2015070034 A1 20150514; ZA 201705288 B 20190227
DOCDB simple family (application)
US 201414535953 A 20141107; AU 2014346591 A 20141107; AU 2018282446 A 20181221; AU 2020257084 A 20201021; CA 2929655 A 20141107; DK 14802771 T 20141107; EP 14802771 A 20141107; EP 19207221 A 20141107; ES 14802771 T 20141107; HU E14802771 A 20141107; JP 2016528225 A 20141107; JP 2017213633 A 20171106; JP 2020069560 A 20200408; JP 2021156357 A 20210927; LT 14802771 T 20141107; PL 14802771 T 20141107; PT 14802771 T 20141107; SI 201431469 T 20141107; US 2014064581 W 20141107; US 201414535855 A 20141107; US 201715459840 A 20170315; US 201715481728 A 20170407; US 201916443793 A 20190617; US 202117216285 A 20210329; US 202318488215 A 20231017; ZA 201705288 A 20170804